Journey Medical Corp Announces New Journey with the Experts Video Featuring Maria Hicks, MD — Journey Medical Corporation

Dr. Hicks discusses eczema, a skin condition affecting 35 million people in the United States

 

 

SCOTTSDALE, Ariz.Oct. 30, 2020PRLog — Journey Medical Corporation today released a new Journey with the Experts video featuring Maria Hicks, MD, a board-certified dermatologist with ForCare Medical Center in Tampa. Dr. Hicks sits down with Journey Medical to discuss eczema, including what it is, why it occurs and how those affected can seek treatment from their local dermatology practice.

Eczema is a chronic inflammatory skin condition that affects an estimated 35 million people in the United States. It affects 10-20 percent of children, but can occur at any age.

To view the Journey with the Experts video featuring Dr. Hicks, please visit https://vimeo.com/472829843/8422e18397.

About Journey with the Experts

Journey with the Experts is an educational initiative supported by Journey Medical Corporation, the medical dermatology company. The initiative is designed to educate the general public on common medical dermatology skin disorders and explain how these conditions can be treated at local dermatology practices.

About Journey Medical Corporation

Journey Medical is focused on identifying, acquiring and strategically commercializing innovative, differentiated dermatology products through its efficient sales and marketing model. The company currently markets five products that help treat and heal common skin conditions. The Journey Medical team is comprised of industry experts with extensive experience commercializing some of the most successful prescription dermatology brands. Journey Medical is located in Scottsdale, Arizona and is a partner company of Fortress Biotech, Inc. (NASDAQ:FBIO). For additional information about Journey Medical Corporation, visit https://journeymedicalcorp.com/.

About Maria Hicks, MD

Maria I. Hicks, MD is an award-winning, board-certified Dermatologist, fluent in Spanish and English. She earned her medical degree from Instituto de Ciencias de la Salud CES in Medellin, Colombia (South America), where she also completed her dermatology training and served as chief resident. After moving to the United States in 2002 from Colombia, Dr. Hicks completed a three-year program in clinical research with the Dermatology Department at Wake Forest University in North Carolina. Her extensive written works about dermatology have been published in numerous publications, in both English and Spanish, such as national dermatology journals and medical books. Dr. Hicks completed two years of Internal Medicine Residency at Geisinger Medical Center in Danville, Pennsylvania, followed by a dermatology residency. Dr. Hicks treats all aspects of dermatology, including the prevention, detection and treatment of skin cancer, as well as other disorders of the skin, hair and nails. She has a special interest in cosmetic dermatology, fillers, Botox®, chemical peels and lasers. For additional information about Dr. Hicks, please visit https://forcaremed.com/medical-practice/providers/maria-hicks-md/.

Forward Looking Statements

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. As used below and throughout this press release, the words “we”, “us” and “our” may refer to Fortress individually, a partner company individually, or Fortress together with one or more partner companies, as dictated by context. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; risks relating to the timing of starting and completing clinical trials; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law.

LEAVE A REPLY

Please enter your comment!
Please enter your name here